Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Rohto Pharmaceutical Co stock price, quote, forecast and news

4527.T
JP3982400008
858075

Price

3,471.00
Today +/-
+0
Today %
+0 %
P

Rohto Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Rohto Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rohto Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rohto Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Rohto Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Rohto Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Rohto Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rohto Pharmaceutical Co’s growth potential.

Rohto Pharmaceutical Co Revenue, EBIT and net profit per share

DateRohto Pharmaceutical Co RevenueRohto Pharmaceutical Co EBITRohto Pharmaceutical Co Net Income
2027e360 B undefined0 undefined42.6 B undefined
2026e335.29 B undefined0 undefined39.18 B undefined
2025e305.8 B undefined0 undefined34.67 B undefined
2024270.84 B undefined40.05 B undefined30.94 B undefined
2023238.66 B undefined33.96 B undefined26.38 B undefined
2022199.65 B undefined29.02 B undefined21.13 B undefined
2021181.29 B undefined22.99 B undefined16.74 B undefined
2020188.33 B undefined22.56 B undefined15.41 B undefined
2019183.58 B undefined20.81 B undefined9.8 B undefined
2018171.74 B undefined19.09 B undefined9.29 B undefined
2017154.6 B undefined15.45 B undefined10.01 B undefined
2016167.02 B undefined15.68 B undefined9.1 B undefined
2015151.77 B undefined13.16 B undefined8.63 B undefined
2014143.82 B undefined16.82 B undefined8.95 B undefined
2013129.15 B undefined14.38 B undefined8.09 B undefined
2012120.29 B undefined13.62 B undefined8.18 B undefined
2011115.47 B undefined13.11 B undefined7.97 B undefined
2010113.43 B undefined12.55 B undefined7.77 B undefined
2009110.61 B undefined11.64 B undefined6.14 B undefined
2008108.13 B undefined12.37 B undefined7.53 B undefined
200795.62 B undefined10.58 B undefined6.62 B undefined
200685.85 B undefined9.82 B undefined6.48 B undefined
200573.33 B undefined8.01 B undefined5.44 B undefined

Rohto Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
44.2349.5851.8355.7259.562.9465.9267.3873.3385.8595.62108.13110.61113.43115.47120.29129.15143.82151.77167.02154.6171.74183.58188.33181.29199.65238.66270.84305.8335.29360
-12.114.547.496.805.784.742.218.8417.0811.3713.092.292.551.804.177.3611.365.5310.04-7.4311.096.892.58-3.7410.1319.5413.4812.919.647.37
64.3562.8162.5861.0759.8757.0260.3461.6763.6162.4261.0859.1358.9658.8759.0258.4959.1259.7359.5559.7359.0958.8159.6660.6359.0058.1957.5858.07---
28.4631.1432.4434.0335.6335.8939.7841.5546.6553.5958.463.9465.2166.7868.1570.3676.3585.990.3899.7791.35101109.53114.19106.96116.17137.42157.29000
4.644.254.674.755.484.336.245.898.019.8210.5812.3711.6412.5513.1113.6214.3816.8213.1615.6815.4519.0920.8122.5622.9929.0233.9640.05000
10.508.589.028.539.206.889.468.7410.9311.4411.0611.4410.5311.0611.3611.3211.1311.708.679.399.9911.1111.3411.9812.6814.5314.2314.79---
1.971.871.662.883.322.29-1.333.725.446.486.627.536.147.777.978.188.098.958.639.110.019.299.815.4116.7421.1326.3830.9434.6739.1842.6
--5.32-11.3573.6715.37-30.95-158.14-379.2046.3019.062.1513.72-18.4226.542.552.74-1.1910.63-3.535.4110.04-7.215.4957.268.6526.1824.8517.2812.0813.008.73
-------------------------------
-------------------------------
107114113113114112107117117118118118118118118118118116113.97114.16228.64228.8228.79228.79228.8228.8228.8228.8000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Rohto Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Rohto Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Rohto Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Rohto Pharmaceutical Co's financial health and stability.

Assets

Rohto Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Rohto Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Rohto Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Rohto Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
5.15.84.090.055.868.289.810.7612.379.2412.4113.4314.0913.6314.613.7514.314.7516.8216.321.7323.0127.9534.29
3.393.363.282.913.473.113.243.534.415.695.574.465.145.455.936.86.455.925.916.46.946.757.677.8
000000000000000000000000
-3,715-4,9822243676-5,990-4,501-5,062-3,592-10,237-3,317-5,354-9,001-3,956-2,400-8,476-11,238-8,039-5,735-4,876-10,482-10,238-10,167-12,278
-0.13-0.230.24.48-0.361.32-0.890.12-0.582.670.430.380.171.631.02-0.381.850.812.633.920.920.561.791.11
541509407266173192471634586480366362228187195217174141147150130143228247
3.421.752.851.821.531.254.073.564.085.123.374.846.315.315.885.472.536.115.155.956.627.778.736.94
4.653.967.597.489.646.727.659.3612.617.3615.0912.9210.3916.7519.1411.6911.3613.4519.6321.7419.1120.0827.2530.93
-5,471-3,623-3,262-5,228-2,466-10,951-9,002-4,249-3,743-6,372-4,815-8,784-8,682-5,403-6,709-4,147-4,731-3,980-5,452-6,917-6,433-10,304-11,328-9,908
-4,119-3,937-1,562-6,532-3,607-11,466-9,261-7,525-3,981-8,995-5,714-8,585-9,605-10,595-12,620-9,024-6,066-9,511-11,014-10,245-9,405-10,237-16,406-13,176
1.35-0.311.7-1.3-1.14-0.52-0.26-3.28-0.24-2.62-0.90.2-0.92-5.19-5.91-4.88-1.34-5.53-5.56-3.33-2.970.07-5.08-3.27
000000000000000000000000
-0.52-0.14-3.19-0.67-3.56.660.27-0.33-4.260.07-0.26-1.832.61-1.492.25-1.61-3.9-0.310.74-0.641.670.837.59-9.88
0175-193700331181600000-5,319334245268300000
-1.26-0.63-4.21-1.49-4.315.92-0.51-1.5-5.66-1.37-1.94-3.30.8-3.41-5.21-3.38-5.9-2.34-1.82-3.39-1.6-2.353.47-16.2
-121-25-26-1559-14-48-31-39-3817673-39-21-4834-20-57-244-194-216-698-1,641
-721-668-805-802-801-801-1,090-1,145-1,386-1,400-1,646-1,646-1,881-1,881-2,116-2,050-2,278-2,278-2,506-2,506-3,078-2,965-3,422-4,676
-1.08-0.391.98-0.781.531.08-1.760.452.6-3.667.220.731.384.493.162.07-2.60.976.67.287.327.5918.656.79
-8233324,3232,2547,173-4,235-1,3565,1078,86599010,2784,1371,70811,34412,4327,5436,6339,47014,17314,82712,6769,77315,92321,017
000000000000000000000000

Rohto Pharmaceutical Co stock margins

The Rohto Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rohto Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rohto Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Rohto Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Rohto Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Rohto Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Rohto Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rohto Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rohto Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rohto Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Rohto Pharmaceutical Co Margin History

Rohto Pharmaceutical Co Gross marginRohto Pharmaceutical Co Profit marginRohto Pharmaceutical Co EBIT marginRohto Pharmaceutical Co Profit margin
2027e58.07 %0 %11.83 %
2026e58.07 %0 %11.69 %
2025e58.07 %0 %11.34 %
202458.07 %14.79 %11.42 %
202357.58 %14.23 %11.05 %
202258.19 %14.53 %10.58 %
202159 %12.68 %9.24 %
202060.63 %11.98 %8.18 %
201959.66 %11.34 %5.34 %
201858.81 %11.11 %5.41 %
201759.09 %9.99 %6.48 %
201659.73 %9.39 %5.45 %
201559.55 %8.67 %5.69 %
201459.73 %11.7 %6.22 %
201359.12 %11.13 %6.26 %
201258.49 %11.32 %6.8 %
201159.02 %11.36 %6.9 %
201058.87 %11.06 %6.85 %
200958.96 %10.53 %5.55 %
200859.13 %11.44 %6.96 %
200761.08 %11.06 %6.92 %
200662.42 %11.44 %7.55 %
200563.61 %10.93 %7.42 %

Rohto Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Rohto Pharmaceutical Co earnings per share therefore indicates how much revenue Rohto Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rohto Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rohto Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rohto Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rohto Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Rohto Pharmaceutical Co Revenue, EBIT and net profit per share

DateRohto Pharmaceutical Co Sales per ShareRohto Pharmaceutical Co EBIT per shareRohto Pharmaceutical Co Earnings per Share
2027e1,577.98 undefined0 undefined186.73 undefined
2026e1,469.7 undefined0 undefined171.74 undefined
2025e1,340.42 undefined0 undefined151.98 undefined
20241,183.74 undefined175.04 undefined135.21 undefined
20231,043.12 undefined148.42 undefined115.29 undefined
2022872.58 undefined126.81 undefined92.34 undefined
2021792.34 undefined100.48 undefined73.18 undefined
2020823.16 undefined98.59 undefined67.36 undefined
2019802.4 undefined90.96 undefined42.83 undefined
2018750.63 undefined83.42 undefined40.6 undefined
2017676.17 undefined67.58 undefined43.78 undefined
20161,462.99 undefined137.38 undefined79.69 undefined
20151,331.69 undefined115.46 undefined75.73 undefined
20141,239.84 undefined145.01 undefined77.13 undefined
20131,094.46 undefined121.86 undefined68.53 undefined
20121,019.42 undefined115.45 undefined69.36 undefined
2011978.58 undefined111.12 undefined67.51 undefined
2010961.26 undefined106.36 undefined65.83 undefined
2009937.38 undefined98.67 undefined52.03 undefined
2008916.36 undefined104.86 undefined63.77 undefined
2007810.33 undefined89.64 undefined56.08 undefined
2006727.58 undefined83.22 undefined54.9 undefined
2005626.76 undefined68.48 undefined46.5 undefined

Rohto Pharmaceutical Co business model

Rohto Pharmaceutical Co Ltd is a leading Japanese company in the pharmaceutical and cosmetic products industry, founded in 1899. The company was originally established as a small company to manufacture herbal medicine before undergoing several mergers and acquisitions to become the company we know today. Rohto Pharmaceutical's business model focuses on developing and marketing innovative products for health and beauty. The company has a global reputation for its high-quality products that undergo stringent testing to ensure they are safe and effective. Rohto Pharmaceutical has various business divisions. One of the main areas is the pharmaceutical division, which manufactures medications for various ailments, including ophthalmology, pain relief, and skincare. Another important business area is Rohto Pharmaceutical's cosmetics division, which offers a wide range of facial care products, sunscreen, and whitening products. The company is known for its lotions and emulsions that are based on high-quality ingredients such as vitamin C, hyaluronic acid, and collagen. Over the years, Rohto Pharmaceutical has also launched several groundbreaking products. For example, the company developed the world's first eye drop product for dry eyes. Another groundbreaking invention by Rohto is the invention of menthol cooling effects in eye drops, which are intended to provide a refreshing sensation in the eyes. Rohto Pharmaceutical has developed innovative technologies and production facilities with cleanroom laboratories for pharmaceutical and cosmetic products. The company's technological advancements also include the development of hybrid companies that combine the competencies of pharmacists and cosmetologists, facilitating the development of products for the beauty and health sectors. Although Rohto Pharmaceutical has focused its efforts on the Japanese market, the company has also opened branches in other countries, including the USA, Europe, and Asia. As a result, Rohto offers a wide range of products such as menthol spray, sunscreen, and eye drops that are sold worldwide. Conclusion: Rohto Pharmaceutical is a leading provider of pharmaceutical and cosmetic products. The company has built its reputation based on its innovative products, stringent quality controls, and groundbreaking technologies. Rohto Pharmaceutical has a vision that encompasses "building health, creating beauty, and making life easier." By dividing its business into various divisions, the company is able to offer a wide range of health and beauty products to meet customer needs. Rohto Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Rohto Pharmaceutical Co SWOT Analysis

Strengths

1. Strong presence in the pharmaceutical industry, with a broad range of healthcare products and medications.

2. Well-established brand reputation and customer trust.

3. Robust research and development capabilities, leading to innovative product offerings.

4. Extensive distribution network, allowing for widespread availability of products.

Weaknesses

1. Limited geographical presence outside of Japan, potentially hindering international growth opportunities.

2. Dependence on a few key products, which increases vulnerability to market fluctuations and competition.

3. Inconsistent marketing and branding strategies, leading to fragmented messaging.

4. Relatively higher production costs compared to some competitors.

Opportunities

1. Growing global demand for healthcare products, presenting expansion opportunities in international markets.

2. Increasing focus on health and wellness, providing scope for new product development.

3. Strategic partnerships and collaborations to enhance research capabilities and market reach.

4. The rise of e-commerce platforms, enabling direct-to-consumer sales and improved accessibility.

Threats

1. Intense competition within the pharmaceutical industry, with both domestic and international players.

2. Stringent regulations and compliance requirements, increasing operational costs and time-to-market.

3. Potential impact of adverse events and product recalls on the company's reputation and financial stability.

4. Economic uncertainties and fluctuations affecting consumer spending patterns.

Rohto Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Rohto Pharmaceutical Co shares outstanding

The number of shares was Rohto Pharmaceutical Co in 2023 — This indicates how many shares 228.798 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rohto Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rohto Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rohto Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rohto Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Rohto Pharmaceutical Co Stock splits

In Rohto Pharmaceutical Co's history, there have been no stock splits.

Rohto Pharmaceutical Co dividend history and estimates

In 2023, Rohto Pharmaceutical Co paid a dividend amounting to 24 JPY. Dividend means that Rohto Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Rohto Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Rohto Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Rohto Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Rohto Pharmaceutical Co Dividend History

DateRohto Pharmaceutical Co Dividend
2027e32.05 undefined
2026e32.06 undefined
2025e32.04 undefined
202430 undefined
202324 undefined
202241 undefined
202130 undefined
202026 undefined
201914 undefined
201822 undefined
201722 undefined
201620 undefined
201520 undefined
201418 undefined
201318 undefined
201216 undefined
201116 undefined
201014 undefined
200910 undefined
200812 undefined
200712 undefined
20067.5 undefined
200512.5 undefined

Rohto Pharmaceutical Co dividend payout ratio

In 2023, Rohto Pharmaceutical Co had a payout ratio of 41.33%. The payout ratio indicates the percentage of the company's profits that Rohto Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Rohto Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Rohto Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Rohto Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Rohto Pharmaceutical Co Payout Ratio History

DateRohto Pharmaceutical Co Payout ratio
2027e42.33 %
2026e42.08 %
2025e42.66 %
202442.24 %
202341.33 %
202244.4 %
202141 %
202038.6 %
201932.69 %
201854.19 %
201750.25 %
201625.1 %
201526.41 %
201423.34 %
201326.27 %
201223.07 %
201123.7 %
201021.27 %
200919.22 %
200818.82 %
200721.4 %
200613.66 %
200526.88 %
Unfortunately, there are currently no price targets and forecasts available for Rohto Pharmaceutical Co.

Rohto Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/202421.44 20.95  (-2.3 %)2024 Q4
9/30/202328.65 32.89  (14.8 %)2024 Q2
6/30/202327.9 39.85  (42.85 %)2024 Q1
3/31/20237.07 20.78  (193.87 %)2023 Q4
12/31/202235.86 37.01  (3.22 %)2023 Q3
9/30/202223.25 27.17  (16.87 %)2023 Q2
3/31/202219.04 17.91  (-5.95 %)2022 Q4
12/31/202119.49 27.08  (38.9 %)2022 Q3
9/30/202118.58 26.41  (42.11 %)2022 Q2
6/30/202122.14 41.48  (87.36 %)2022 Q1
1
2
3

Rohto Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
7.56 % MFS Investment Management17,256,900-2,557,50011/15/2023
5.13 % SPARX Asset Management Co., Ltd.11,707,400-2,513,6002/15/2023
3.54 % Mitsubishi UFJ Trust and Banking Corporation8,077,6008,077,60010/31/2022
3.33 % MUFG Bank, Ltd.7,601,00009/30/2023
2.96 % Nomura Asset Management Co., Ltd.6,750,90943,5003/31/2024
2.60 % Yamada (Kiyoko)5,938,0001,0009/30/2023
2.46 % Yamada Kousan5,616,0001,0009/30/2023
2.40 % The Vanguard Group, Inc.5,467,33635,0003/31/2024
2.23 % Sansho Kosan KK5,096,00009/30/2023
1.86 % Nippon Life Insurance Company4,238,00009/30/2023
1
2
3
4
5
...
10

Rohto Pharmaceutical Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
MatsukiyoCocokara Stock
MatsukiyoCocokara
SupplierCustomer0,860,730,100,52-0,20-0,25
Japan Tobacco Stock
Japan Tobacco
SupplierCustomer0,650,35-0,65-0,64-0,050,05
D Western Therapeutics Stock
D Western Therapeutics
SupplierCustomer0,540,04-0,20-0,29-0,68-0,10
Yonyu Plastics Stock
Yonyu Plastics
SupplierCustomer0,43-0,060,660,650,520,21
Shionogi Stock
Shionogi
SupplierCustomer0,410,010,790,240,760,57
Nippon Shinyaku Stock
Nippon Shinyaku
SupplierCustomer0,31-0,30-0,330,11-0,040,35
Pharma Foods Intl Stock
Pharma Foods Intl
SupplierCustomer0,210,100,370,06-0,47-0,57
Ohki Health Care Holdings Stock
Ohki Health Care Holdings
SupplierCustomer-0,080,020,06-0,23-0,68-0,37
Morishita Jintan Stock
Morishita Jintan
SupplierCustomer-0,090,010,760,51-0,46-0,42
Soho Global Health Stock
Soho Global Health
SupplierCustomer-0,13-0,160,69-0,04-0,49-0,69
1
2

Most common questions regarding Rohto Pharmaceutical Co

What values and corporate philosophy does Rohto Pharmaceutical Co represent?

Rohto Pharmaceutical Co Ltd represents a set of values and corporate philosophy that focuses on improving people's lives through innovative healthcare products. The company is committed to providing safe, effective, and high-quality solutions to meet various medical and beauty needs. Rohto Pharmaceutical Co Ltd believes in continuous research and development, ensuring that their products are backed by scientific expertise. With a strong emphasis on customer satisfaction, the company aims to contribute to society by promoting better health and well-being. Rohto Pharmaceutical Co Ltd's dedication to excellence and its mission to enhance the lives of individuals make it a trusted name in the pharmaceutical industry.

In which countries and regions is Rohto Pharmaceutical Co primarily present?

Rohto Pharmaceutical Co Ltd is primarily present in Japan, its home country. As a leading pharmaceutical company, Rohto has established its presence and reputation domestically. With a strong focus on developing and marketing innovative healthcare products, Rohto has gained a significant market share in Japan. The company's commitment to providing high-quality healthcare solutions has made it a trusted brand among consumers in the region. Rohto continues to expand its operations and aims to bring its products to other countries and regions in the future.

What significant milestones has the company Rohto Pharmaceutical Co achieved?

Rohto Pharmaceutical Co Ltd, a renowned company in the pharmaceutical industry, has achieved several significant milestones. The company has successfully expanded its global presence through strategic partnerships and acquisitions, strengthening its position in the market. Rohto Pharmaceutical Co Ltd has also developed innovative and high-quality healthcare products, addressing various medical needs. With a focus on research and development, the company has made breakthroughs in the pharmaceutical sector, contributing to advancements in healthcare. Moreover, Rohto Pharmaceutical Co Ltd has gained recognition for its commitment to ensuring the well-being and satisfaction of its customers worldwide.

What is the history and background of the company Rohto Pharmaceutical Co?

Rohto Pharmaceutical Co Ltd, founded in 1899, is a well-established Japanese healthcare company. With a rich history spanning over a century, the company has garnered a reputation for manufacturing and distributing innovative pharmaceutical products globally. Rohto Pharmaceutical specializes in developing healthcare solutions across various domains, including skincare, eye care, oral care, and pain relief. With a strong commitment to research and development, the company consistently delivers high-quality, reliable products that cater to diverse consumer needs. Over the years, Rohto Pharmaceutical has become synonymous with excellence in the healthcare industry, consistently striving to improve the overall well-being and health of individuals worldwide.

Who are the main competitors of Rohto Pharmaceutical Co in the market?

The main competitors of Rohto Pharmaceutical Co Ltd in the market include Johnson & Johnson, Pfizer Inc., Novartis International AG, and GlaxoSmithKline plc.

In which industries is Rohto Pharmaceutical Co primarily active?

Rohto Pharmaceutical Co Ltd is primarily active in the healthcare and personal care industries.

What is the business model of Rohto Pharmaceutical Co?

The business model of Rohto Pharmaceutical Co Ltd revolves around developing, manufacturing, and marketing a wide range of innovative healthcare products. Rohto Pharmaceutical aims to contribute to the well-being of individuals by providing high-quality medicines, cosmetics, and functional foods. As a leading Japanese company in the pharmaceutical industry, Rohto Pharmaceutical focuses on research and development to create breakthrough solutions for various health concerns. With a strong commitment to improving people's lives, Rohto Pharmaceutical continues to expand its product portfolio while ensuring adherence to strict quality standards.

What is the P/E ratio of Rohto Pharmaceutical Co 2024?

The Rohto Pharmaceutical Co P/E ratio is 25.67.

What is the P/S ratio of Rohto Pharmaceutical Co 2024?

The Rohto Pharmaceutical Co P/S ratio is 2.93.

What is the AlleAktien quality score of Rohto Pharmaceutical Co?

The AlleAktien quality score for Rohto Pharmaceutical Co is 9/10.

What is the revenue of Rohto Pharmaceutical Co 2024?

The Rohto Pharmaceutical Co revenue is 270.84 B JPY.

How high is the profit of Rohto Pharmaceutical Co 2024?

The Rohto Pharmaceutical Co profit is 30.94 B JPY.

What is the business model of Rohto Pharmaceutical Co

Rohto Pharmaceutical Co Ltd is a Japanese company specializing in the manufacturing and sale of healthcare products. It was founded in 1899 and has its headquarters in Osaka, Japan. It is part of the Rohto-Mentholatum group and operates worldwide. The company's main divisions are ophthalmic, dermatological, and oral care products. In the ophthalmic division, Rohto Pharmaceutical holds a leading position in the Japanese market, offering eye drops, lens care products, and eye washes for both medical and cosmetic purposes. In dermatology, the company provides various skin creams, pain ointments, and lip balms to help with skin issues such as acne, eczema, psoriasis, and other irritations. Their oral care products include toothpaste, mouthwash, and gum. Rohto Pharmaceutical also offers a range of pain relievers for headaches, backaches, muscle pains, and menstrual discomfort, marketed under brand names such as "Zanidip" and "Sai-Ro." With a strong presence in the Asian market, Rohto Pharmaceutical continues to expand into North America and Europe. It has subsidiaries in China, Hong Kong, Taiwan, and Thailand, as well as branches in North America and Europe. The company has partnerships with local businesses in various countries and operates joint ventures to expand its global presence. Rohto Pharmaceutical's business model relies on innovation and quality control. It invests in research and development to develop new products and improve existing ones. The company also implements rigorous controls in all its production facilities to ensure its products meet the highest quality standards. Rohto Pharmaceutical holds multiple patents for its products and technologies. The company is known for its marketing strategies, prioritizing brand awareness and utilizing various media to promote its products. It also maintains a presence on social media and employs online marketing to sell its products. Rohto Pharmaceutical is expected to continue expanding and entering new markets. With a strong position in the Asian market, it is likely to focus on expanding in North America and Europe. Continued investment in research and development and the introduction of new products are also expected to drive the company's growth. Overall, the future of Rohto Pharmaceutical is promising, and it is expected to remain a significant player in the healthcare industry.

What is the Rohto Pharmaceutical Co dividend?

Rohto Pharmaceutical Co pays a dividend of 41 JPY distributed over 2 payouts per year.

How often does Rohto Pharmaceutical Co pay dividends?

Rohto Pharmaceutical Co pays out a dividend 2 times a year.

What is the Rohto Pharmaceutical Co ISIN?

The ISIN of Rohto Pharmaceutical Co is JP3982400008.

What is the Rohto Pharmaceutical Co WKN?

The WKN of Rohto Pharmaceutical Co is 858075.

What is the Rohto Pharmaceutical Co ticker?

The ticker of Rohto Pharmaceutical Co is 4527.T.

How much dividend does Rohto Pharmaceutical Co pay?

Over the past 12 months, Rohto Pharmaceutical Co paid a dividend of 30 JPY . This corresponds to a dividend yield of about 0.86 %. For the coming 12 months, Rohto Pharmaceutical Co is expected to pay a dividend of 32.04 JPY.

What is the dividend yield of Rohto Pharmaceutical Co?

The current dividend yield of Rohto Pharmaceutical Co is 0.86 %.

When does Rohto Pharmaceutical Co pay dividends?

Rohto Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Rohto Pharmaceutical Co?

Rohto Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Rohto Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 32.04 JPY are expected. This corresponds to a dividend yield of 0.92 %.

In which sector is Rohto Pharmaceutical Co located?

Rohto Pharmaceutical Co is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Rohto Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rohto Pharmaceutical Co from 12/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Rohto Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Rohto Pharmaceutical Co in the year 2023?

In the year 2023, Rohto Pharmaceutical Co distributed 24 JPY as dividends.

In which currency does Rohto Pharmaceutical Co pay out the dividend?

The dividends of Rohto Pharmaceutical Co are distributed in JPY.

All fundamentals about Rohto Pharmaceutical Co

Our stock analysis for Rohto Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rohto Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.